GlassScriptPhysician profile
Daneb Gonzalez
NPI 1548572506
$8,127.91
in general payments reported to CMS, 2019-2025
25 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 98% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,329 · 2022: $1,224 · 2023: $1,649 · 2024: $2,464 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,575.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,337.45 | 2021-2025 | Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $2,069.50 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $903.14 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $349.58 | 2022-2024 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $344.15 | 2022 | |
| Neurelis, INC. | $309.43 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $263.09 | 2022-2025 | |
| Tris Pharma INC | $229.33 | 2021-2024 | Dyanavel Xr |
| Biohaven Pharmaceuticals, INC. | $204.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.94 | 2021-2022 | |
| Abbvie INC. | $149.03 | 2021-2024 | |
| Allergan, INC. | $86.47 | 2021 | |
| Sk Life Science, INC. | $84.96 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $79.98 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $77.82 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $72.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $69.42 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $68.49 | 2022-2025 | |
| Lilly USA, LLC | $54.64 | 2021-2023 | Emgality |
| Aprecia Pharmaceuticals, LLC | $44.20 | 2021-2023 | Spritam |
| Scilex Pharmaceuticals INC. | $43.98 | 2023-2024 | Ztlido |
| Otter Pharmaceuticals, LLC | $39.41 | 2025 | Sympazan |
| Immedica Pharma US, INC. | $29.51 | 2023 | |
| Noven Therapeutics, LLC | $23.91 | 2024 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $13.91 | 2025 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daneb Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.